Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
Gail M GauvreauJens M HohlfeldMark J FitzGeraldLouis-Philippe BouletDonald W CockcroftBeth E DavisStephanie KornOliver KornmannRichard LeighIrvin MayersHenrik WatzSarah S GrantMonish JainMaciej CabansekiPeter E PertelIeuan JonesJean R LecotHui CaoPaul M O'ByrnePublished in: The European respiratory journal (2023)
Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation and was safe in subjects with mild atopic asthma.